文献速递其他结缔组织病

利妥昔单抗治疗早期系统性硬化症

Rituximab in early systemic sclerosis.
PubMed 文献 · RMD Open · 2017-07-28

一项24个月、随机双盲安慰剂对照单中心小样本试验纳入16例诊断<2年的系统性硬化症患者,评估利妥昔单抗(RTX)预防纤维化并发症的效力及可接受性与可行性。结果显示RTX未出现非预期安全性问题,但皮肤评分组间无差异,肺功能与肺受累程度在RTX组略有改善但差异不显著;作者认为该小样本试验无法确认或否定RTX潜在疗效,值得在肺受累亚组开展进一步安慰剂对照试验。

要点

  • RTX在早期SSc中未观察到非预期安全性问题。
  • 皮肤评分随时间变化组间无差异。
  • FVC与肺受累程度在RTX组略改善但差异不显著。

核心结论

  • RTX在早期SSc中未出现非预期安全性问题。
  • 该小样本试验无法确认或否定RTX的潜在疗效。
  • 未来值得在肺受累亚组开展安慰剂对照试验。

研究设计与样本

  • 24个月、随机、双盲、安慰剂对照、单中心试验。
  • 纳入诊断<2年的SSc患者,共16例(RTX组8例,安慰剂组8例)。
  • RTX或安慰剂于第0天、第15天及第6个月输注。
  • 每3个月临床评估,隔次访视行肺功能检查与高分辨率CT。
  • 基线与第3个月行皮肤活检,除第9、18个月外每次访视行外周血单个核细胞免疫表型分析。

主要发现

  • 共发生11例严重不良事件(RTX组7例,安慰剂组4例,p=0.36)。
  • 未观察到非预期的RTX相关事件。
  • 皮肤评分随时间变化组间无差异。
  • 随时间推移,用力肺活量与肺受累范围在RTX组略有改善,但差异不显著。

临床怎么用

  • 早期SSc使用RTX需关注安全性监测,本试验未出现非预期事件。
  • RTX对皮肤评分未见优于安慰剂,不应据此常规用于皮肤病变。
  • 肺受累患者可考虑纳入进一步安慰剂对照试验评估RTX疗效。

局限性

  • 样本量小(共16例),无法确认或否定RTX潜在疗效。
  • 单中心设计。
  • 肺功能与肺受累改善差异不显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: (1) Hypothesis testing of the potency of rituximab (RTX) in preventing fibrotic complications and (2) assessing acceptability and feasibility of RTX in early systemic sclerosis (SSc). METHODS: A small, 24-month, randomised, double-blind, placebo-controlled, single-centre trial in patients with SSc diagnosed <2 years was conducted. Patients received RTX or placebo infusions at t=0, t=15 days and t=6 months. Patients were clinically evaluated every 3 months, with lung function tests and high-resolution CT every other visit. Skin biopsies were taken at baseline and month 3. Immunophenotyping of peripheral blood mononuclear cells was performed at every visit, except at months 9 and 18. Adverse events, course of skin and pulmonary involvement and B cell populations in skin and peripheral blood were evaluated. RESULTS: In total 16, patients (rituximab n=8, placebo n=8) were included. Twelve patients had diffuse cutaneous SSc. Eighty-eight adverse events (RTX n=53, placebo n=35, p=0.22) and 11 serious adverse events (RTX n=7, placebo n=4, p=0.36) occurred. No unexpected RTX-related events were observed. Mean skin score over time did not differ between the groups. Over time, forced vital capacity and extent of lung involvement slightly improved with RTX, but this difference was insignificant. In peripheral blood B cells depletion was demonstrated. CONCLUSIONS: No unexpected safety issues were observed with RTX in early SSc. Although this small trial could not confirm or reject potential efficacy of RTX in these patients, future placebo-controlled trials are warranted, specifically in the subgroup of patients with pulmonary involvement. TRIAL REGISTRATION NUMBER: EudraCT 2008-07180-16; Results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Boonstra M, Meijs J, Dorjée AL, et al. Rituximab in early systemic sclerosis. RMD Open. 2017. PMID: 28879049. doi:10.1136/rmdopen-2016-000384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。